Huahai Pharmaceuticals (600521.SH): The company is actively promoting its third transformation and upgrade from generic drugs to innovative drugs. There are risks such as the clinical trial progress not meeting expectations.

Wisdom Financial News APP News, Huahai Pharmaceutical (600521.SH) issued a stock price abnormality announcement stating that the company is actively promoting the third transformation and upgrade from generic drugs to innovative drugs. In recent years, the company has diversified through various channels and resources, increased efforts, and accelerated the development speed of innovative drugs. However, the development of new products in the pharmaceutical industry is characterized by high technical difficulty, large initial investment, long approval cycles, and various uncertainties such as technical and regulatory factors from early development to clinical trials, registration declaration, and industrial production. The competition situation of future products will also change with the market. Specific risk factors include but are not limited to: